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VALORIZATION APPENDIX 
Dementia imposes an enormous social and economic burden on society. 
Over 46 million people suffer from dementia today, and this is expected 
to increase to 131 million by 2050. The worldwide cost of dementia is 
estimated to be US $818, and projected to be a trillion dollar by 2018 
(1). These statistics make finding new cures for dementia a matter of 
urgency and importance to the wellbeing of today’s ageing societies and 
countries healthcare budgets. Unfortunately, although progress has 
been made towards effective therapeutics, no cure for dementia is 
currently available. One of the reasons progress towards a cure has 
been slow is a lack of understanding of the fundamental disease 
processes.  
In this thesis, I describe our research on a novel complement system 
activator, the ceramide transfer protein. This is the first time it has been 
shown that CERT is able to activate complement. Our findings with 
regards to CERT represent an important step in understanding the 
mechanisms of dementia and other diseases, in which complement 
activation via C1q plays an important role (such as systemic lupus 
erythematosus to cancer, kidney disease, organ transplantation, 
pregnancy disorders, multiple sclerosis and severe trauma (2–6). 
Modulating complement activation has potential therapeutic 
applications for these conditions.  
The success of potential therapies for dementia depends on their 
specificity as well as efficiency. In the second part of this thesis, I 
provide an account of our research on targeting nanoparticles to the 
brain for drug delivery, where we attempted to identify nanoparticles 
with the highest specificity. We characterized a range of nanoparticle 
formulations to have varying specificity towards the brain, showing 
that this is a promising drug delivery method, albeit in need of further 
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development. As part of this research we also carried out toxicity tests. 
This type of research in vitro and in animals is an important first step to 
select therapies safe for human use. In spite of not providing clear-cut 
conclusions, this study is an important increment to the field, on which 
future research can be built. 
The work described in this thesis is a combination of basic research 
(Chapters 1 to 3 on the role of CERT in complement activation and 
neurodegenerative disease) as well as research that is more directly 
applicable (Chapters 4 and 5 on nanoparticle targeting). While 
governments and other policy makers, especially in the Netherlands, 
understand the value of applicable biomedical research, they are less 
and less willing to fund basic science. Budgets are increasingly focused 
on applied research that has immediate, direct and tangible benefits to 
society. This is, in my opinion, a worrying trend since basic science is 
essential to long term technological advancement, prosperity and 
improvements to healthcare, even if it provides few short term benefits 
to society. This is illustrated by the way certain important discoveries in 
biomedical science were made, such as the green fluorescent protein 
and Taq DNA polymerase. The first, now ubiquitous in practically every 
laboratory, was discovered by researching how jellyfish glow (7). Taq 
DNA polymerase, essential for PCR, was discovered thermophilic 
bacteria, in the context of a study on the thermal control of 
photosynthesis (8). 
Taken together, I am satisfied that the work presented here constitutes 
contributions to the fields of dementia research and immunology that 
will bring us a step closer to combating this disease. At the same time I 
do hope that society will arrive at the conclusion that basic research, 
however abstract and obscure, is an indispensable element of science.  
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